Journal
ELIFE
Volume 7, Issue -, Pages -Publisher
ELIFE SCIENCES PUBLICATIONS LTD
DOI: 10.7554/eLife.32499
Keywords
-
Categories
Funding
- National Institutes of Health [T32 DA007267, T32GM007767, R37 DA039997]
- American Heart Association [13PRE17110027]
- NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM083118, U19GM106990, T32GM007767] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE ON DRUG ABUSE [T32DA007267, R37DA039997] Funding Source: NIH RePORTER
Ask authors/readers for more resources
The intrinsic efficacy of orthosteric ligands acting at G-protein-coupled receptors (GPCRs) reflects their ability to stabilize active receptor states (R*) and is a major determinant of their physiological effects. Here, we present a direct way to quantify the efficacy of ligands by measuring the binding of a R*-specific biosensor to purified receptor employing interferometry. As an example, we use the mu-opioid receptor (mu-OR), a prototypic class A GPCR, and its active state sensor, nanobody-39 (Nb39). We demonstrate that ligands vary in their ability to recruit Nb39 to mu-OR and describe methadone, loperamide, and PZM21 as ligands that support unique R* conformation(s) of mu-OR. We further show that positive allosteric modulators of mu-OR promote formation of R* in addition to enhancing promotion by orthosteric agonists. Finally, we demonstrate that the technique can be utilized with heterotrimeric G protein. The method is cell-free, signal transduction-independent and is generally applicable to GPCRs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available